Long term effects of vincristine on the peripheral nervous system

Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system. The patients were interviewed with emphasis on neuropath...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuro-oncology Vol. 15; no. 1; pp. 23 - 27
Main Authors:	POSTMA, T. J, BENARD, B. A, HUIJGENS, P. C, OSSENKOPPELE, G. J, HEIMANS, J. J
Format:	Journal Article
Language:	English
Published:	Dordrecht Springer 1993
Subjects:	Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Chemotherapy Cyclophosphamide - administration & dosage Doxorubicin - administration & dosage Female Humans Lymphoma, Non-Hodgkin - complications Lymphoma, Non-Hodgkin - drug therapy Male Medical sciences Methotrexate - administration & dosage Middle Aged Neuromuscular Diseases - chemically induced Neuromuscular Diseases - complications Peripheral Nervous System Diseases - chemically induced Peripheral Nervous System Diseases - complications Pharmacology. Drug treatments Prednisone - administration & dosage Reflex, Abnormal - drug effects Sensation Disorders - chemically induced Sensation Disorders - complications Surveys and Questionnaires Treatment Outcome Vincristine - administration & dosage Vincristine - adverse effects Antineoplastic agent Human Nervous system diseases Toxicity Tumor Hemopathy Peripheral nerve disease Non Hodgkin lymphoma Long term
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system. The patients were interviewed with emphasis on neuropathic symptoms. Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment. Twenty-seven patients reported neuropathic symptoms. In 13 of these 27 patients symptoms were still present at the time of examination. In these patients sensory signs and symptoms predominated. In the other 14 patients symptoms had been present in the past. Symptoms persisted maximally 40 months since cessation of therapy. There was no age difference between patients with and without complaints at the time of examination. Normal reflexes were found in two third of patients. Neuropathic complaints were not very troublesome on the long term. It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.
ISSN:	0167-594X 1573-7373
DOI:	10.1007/bf01050259